Confirmed Control Closed Transaction verified Antifungal TreatmentsConsumerConsumer Healthcare / OTC PharmaceuticalsDermatologyOTC Medicines
Lamisil acquired by Karo Healthcare
Karo Healthcare acquired Lamisil, a consumer healthcare / otc pharmaceuticals brand, on Aug 1, 2023.
Transaction summary
- Target
- Lamisil
- Acquirer
- Karo Healthcare
- Seller
- Haleon
- Announced
- 2023-08-01
- Geography
- -
- Tags
- Antifungal TreatmentsConsumerConsumer Healthcare / OTC PharmaceuticalsDermatologyOTC Medicines
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
4.1x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- A comparable 100% enterprise value has not been established. Separately reported amounts are retained below.
- EV / revenue: 4.1x.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
- User-supplied spreadsheet multiple only; no public revenue, EBITDA, or transaction value support in the fetched evidence.
Source summary
No public source summary has been published for this transaction yet.